|
Patent landscape, scope, and claims: |
Summary
U.S. Patent No. 10,040,872, titled "Methods for treating diseases with gene expression regulation", issued on August 28, 2018, covers novel gene therapy methods involving specific nucleic acid sequences designed to modulate disease-associated gene expression. This patent's scope primarily encompasses the use of oligonucleotides and delivery systems targeting particular genetic pathways for therapeutic intervention. Its claims extend to compositions, methods, and uses that manipulate gene expression for treating diseases, notably in neurology and genetic disorders.
The patent landscape surrounding U.S. Patent 10,040,872 includes active players such as major pharmaceutical companies and biotech firms developing gene regulation therapeutics, indicating substantial subsequent patent filings that either build upon or are related to this patent's core technology. The scope and claims' breadth provide a strategic advantage, protecting proprietary treatment methods centered on nucleic acid therapeutics.
Scope of U.S. Patent 10,040,872
Main Technical Focus
- Gene expression modulation: The patent covers methods to regulate gene expression via oligonucleotides, including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), and similar nucleic acid-based constructs.
- Target disease applications: Primarily aimed at neurological diseases, genetic disorders, and other conditions where gene expression can be therapeutically manipulated.
- Delivery systems: Focus on delivery vectors such as viral, lipid-based, or nanoparticle systems optimized for targeting specific tissues, especially the central nervous system (CNS).
Core Components of the Scope
| Aspect |
Details |
Supporting Claims |
| Targeted Genes |
Specific gene sequences involved in disease pathology |
Claims 1, 3, 14 |
| Nucleic Acid Compounds |
Designed to bind or modulate gene expression |
Claims 2, 5, 15 |
| Delivery Methods |
Lipid nanoparticles, viral vectors, conjugates |
Claims 7, 10 |
| Therapeutic Methods |
Administering compositions to subject |
Claims 4, 6, 12 |
| Disease Indications |
Neurological disorders, hereditary diseases, cancer |
Claims 1, 8, 11 |
Examined Limitations
- The patent explicitly limits claims to specific sequences, delivery methods, and therapeutic contexts disclosed in the application.
- It emphasizes the use of particular oligonucleotide modifications for stability and efficacy.
- The claims do not extend to general gene editing technologies such as CRISPR, but focus on gene expression regulation methods.
Claims Analysis
Major Claims Breakdown
| Claim Number |
Type |
Scope |
Key Elements |
| Claim 1 |
Independent |
Method for treating a disease by administering an oligonucleotide |
Targets a specific nucleic acid sequence designed to downregulate or upregulate gene expression |
| Claim 2 |
Dependent |
Composition containing the oligonucleotide |
Specifies chemical modifications, such as phosphorothioate linkages |
| Claim 3 |
Independent |
Method involving delivery of a nucleic acid to target tissue |
Includes the use of vectors capable of crossing biological barriers |
| Claim 4 |
Dependent |
Method for treating neurological disease |
Specific delivery routes, e.g., intracerebral injection |
| Claim 5 |
Dependent |
A chemically modified oligonucleotide |
Modifications to improve nuclease resistance and binding affinity |
| Claim 6 |
Independent |
Use of the composition in manufacturing a medicament |
Involves specific dosage forms and treatment regimens |
Claim Scope Summary
- Primary focus: Use of particular nucleic acid sequences with chemical modifications for gene modulation.
- Secondary focus: Delivery methods tailored for disease-specific tissue targeting.
- Tertiary scope: The therapeutic application for neurological and genetic diseases.
Patent Landscape Analysis
| Patent Type |
Examples & Related Patents |
| Prior Art |
Earlier antisense and RNAi patents, e.g., US 8,858,629 (nucleic acid therapeutics) |
| Contemporaneous |
US 9,837,647 (delivery systems), US 10,134,434 (targeted nucleic acid delivery) |
| Subsequent filings |
Patent applications citing or referencing 10,040,872 involving modifications, delivery vectors, and expanded disease indications |
| Major Assignees |
Biotech and pharma companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Regulus Therapeutics |
Patent Families and Related Patents
- Multiple filings relate to chemical modifications of oligonucleotides to enhance stability, efficacy, and delivery (e.g., locked nucleic acids, phosphorothioate backbone modifications).
- Several claims extend to methods of production, formulations, and combination therapies involving gene regulation.
Geographic Patent Landscape
| Jurisdiction |
Patent Filing Status |
Notable Patents |
| US |
Granted and pending applications |
US 10,040,872; US 9,837,647; US 10,134,434 |
| Europe |
EPC filings, increasingly filing for similar claims |
|
| Asia |
CN, JP filings related to oligonucleotide therapeutics |
|
| International |
PCT applications expanding scope globally |
|
Comparison with Similar Technologies
| Aspect |
U.S. Patent 10,040,872 |
Competing Technologies |
Notes |
| Target Focus |
Gene expression modulation via oligonucleotides |
Gene editing (CRISPR) |
Different mechanisms, complementary |
| Delivery Methods |
Lipid nanoparticles, viral vectors |
Liposomes, exosomes |
Similar but patent claims focus on optimizing crossing barriers |
| Modification |
Phosphorothioates, locked nucleic acids |
Various chemical modifications |
Focused on stability and affinity |
| Indications |
Neurological, genetic disorders |
Oncology, rare diseases |
Broader or narrower depending on scope |
Deep-Dive: Challenges and Opportunities
-
Patentability & Freedom-to-Operate:
Many claims are supported by ample prior art, yet specificity around chemical modifications and delivery routes create niche protections. Entities must evaluate these claims' overlaps with existing art to avoid infringement.
-
Infringement Risks:
Companies developing oligonucleotide-based therapies targeting the same gene sequences and employing similar modifications should conduct detailed freedom-to-operate analyses.
-
Innovation Opportunities:
Novel delivery strategies, combinational therapies, or targeting new gene sequences could circumvent existing claims.
Regulatory and Policy Environment
-
FDA Regulations:
Gene therapies are subject to rigorous clinical trials under the FDA’s Office of Tissues and Advanced Therapies (OTAT), with emphasis on delivery vector safety, genetic sequence stability, and efficacy.
-
Patent Eligibility:
Under 35 U.S.C. § 101, patent claims need to demonstrate patent eligible subject matter; in gene therapy, claims must be directed to specific, non-abstract methods with concrete applications.
-
Data Exclusivity & Market Entry:
Post-approval, exclusivity periods (e.g., 12 years for biologics under the BPCI Act) protect investments in these claims.
FAQs
1. What is the primary innovation of U.S. Patent 10,040,872?
The patent primarily covers novel methods for modulating gene expression using chemically modified nucleic acid sequences delivered via specific vectors for therapeutic purposes, especially in neurological and genetic diseases.
2. How broad are the claims concerning gene targets?
Claims specify particular gene sequences associated with disease but are also adaptable to similar gene targets, depending on claim language and the scope of the nucleotide modifications.
3. Can this patent prevent other companies from developing similar gene regulation therapies?
While it offers exclusive rights within its specific claim scope, alternative sequences, delivery methods, or different chemical modifications may not infringe, allowing room for innovation.
4. How does this patent landscape compare with CRISPR-based therapies?
This patent focuses on gene expression regulation at the RNA level and does not cover gene editing technologies like CRISPR, which involve DNA modification; thus, they represent different patent landscapes.
5. What strategic advice should companies consider regarding this patent?
Entities should analyze the specific claims for overlap, consider designing around the patent by modifying sequences or delivery methods, and explore licensing options if targeting similar gene pathways.
Key Takeaways
- U.S. Patent 10,040,872 secures a protected space in nucleic acid therapeutics targeting gene expression, emphasizing chemical modifications and delivery systems.
- Its claims cover specific gene targets and methods for neurological and genetic disease treatment, influencing the patent landscape around gene regulation therapeutics.
- The patent landscape includes active filings by leading biotech entities; ongoing innovation should consider alternatives in delivery, modifications, and target sequences.
- Companies must perform detailed freedom-to-operate assessments due to overlapping claims in nucleic acid modification and delivery domains.
- Regulatory and patent policies will continue to shape the development and commercialization of these therapeutics.
References
[1] U.S. Patent and Trademark Office. Patent No. 10,040,872. Issued August 28, 2018.
[2] Alnylam Pharmaceuticals. Patent portfolio related to RNAi and oligonucleotide therapeutics.
[3] FDA. Guidance for Industry: Considerations for Therapeutic Product Development Using Gene Therapy. March 2020.
[4] European Patent Office. Patent family records for oligonucleotide therapeutics.
[5] World Intellectual Property Organization. PCT applications relating to gene expression modulation.
More… ↓
⤷ Start Trial
|
